EAACI Congress 2025
BackTPS42 - Biologicals 02
Saturday 14 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
D2.353
A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.352
Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.357
Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.355
Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.362
Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis
D2.358
Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.363
Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience
D2.354
Questionnaire survey of new treatments for atopic dermatitis
D2.356
Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.351
Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.359
Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
